Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Carla M.L. Van Herpen, Sanjiv S. Agarwala, Axel Hauschild, Carola Berking, J. Thaddeus Beck, Dirk Schadendorf, Rob Jansen, Paola Queirolo, Paolo A. Ascierto, Christian U. Blank, Michael C. Heinrich, Rupam R. Pal, Adnan Derti, Victor Antona, Heidi Nauwelaerts, Angela Zubel, Reinhard Dummer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF V600 -mutant melanoma. We performed a nonrandomized, open-label phase II study, where 183 metastatic melanoma patients received binimetinib 45 mg / 60 mg twice-daily (BRAF arms), or binimetinib 45 mg twice-daily (NRAS arm). Biomarker analyses were prespecified as secondary and exploratory objectives. Here we report the extent of MAPK pathway inhibition by binimetinib, genetic pathway alterations of interest, and potential predictive markers for binimetinib efficacy. Twenty-five fresh pre- and post-dose tumor sample pairs were collected for biomarker analyses, which included assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor molecular status; and exploration of potential predictive biomarkers of efficacy of binimetinib. The postbaseline pERK and DUSP6 expression decreased across all arms; no association between reduced pERK or DUSP6 levels with clinical efficacy was observed. Genetic aberrations were similar to previously reported data on clinical melanoma samples. Genetic pathway alterations occurred predominantly within CDKN2A/B, PTEN, and TRRAP (BRAF-mutation) and CDKN2A/B, TP53, and NOTCH2 (NRAS-mutation). Several patients with BRAF mutations had amplification of genes on chromosome 7q; these patients tended to have shorter progression-free survival than other patients with BRAF-mutant melanoma. Further analysis of genetic alterations, including amplifications of growth factor genes, will determine utility as biomarkers for efficacy.

Original languageEnglish
Pages (from-to)1850-1859
Number of pages10
JournalOncotarget
Volume10
Issue number19
Publication statusPublished - Mar 1 2019

Fingerprint

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation
MAP Kinase Kinase 1
Neoplasms
Gene Amplification
MEK162
Genes
Disease-Free Survival
Intercellular Signaling Peptides and Proteins
Chromosomes
Biopsy

Keywords

  • Binimetinib
  • Biomarker
  • MEK inhibitor
  • Melanoma
  • Phase II

ASJC Scopus subject areas

  • Oncology

Cite this

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., ... Dummer, R. (2019). Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. Oncotarget, 10(19), 1850-1859.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. / Van Herpen, Carla M.L.; Agarwala, Sanjiv S.; Hauschild, Axel; Berking, Carola; Thaddeus Beck, J.; Schadendorf, Dirk; Jansen, Rob; Queirolo, Paola; Ascierto, Paolo A.; Blank, Christian U.; Heinrich, Michael C.; Pal, Rupam R.; Derti, Adnan; Antona, Victor; Nauwelaerts, Heidi; Zubel, Angela; Dummer, Reinhard.

In: Oncotarget, Vol. 10, No. 19, 01.03.2019, p. 1850-1859.

Research output: Contribution to journalArticle

Van Herpen, CML, Agarwala, SS, Hauschild, A, Berking, C, Thaddeus Beck, J, Schadendorf, D, Jansen, R, Queirolo, P, Ascierto, PA, Blank, CU, Heinrich, MC, Pal, RR, Derti, A, Antona, V, Nauwelaerts, H, Zubel, A & Dummer, R 2019, 'Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma', Oncotarget, vol. 10, no. 19, pp. 1850-1859.
Van Herpen CML, Agarwala SS, Hauschild A, Berking C, Thaddeus Beck J, Schadendorf D et al. Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. Oncotarget. 2019 Mar 1;10(19):1850-1859.
Van Herpen, Carla M.L. ; Agarwala, Sanjiv S. ; Hauschild, Axel ; Berking, Carola ; Thaddeus Beck, J. ; Schadendorf, Dirk ; Jansen, Rob ; Queirolo, Paola ; Ascierto, Paolo A. ; Blank, Christian U. ; Heinrich, Michael C. ; Pal, Rupam R. ; Derti, Adnan ; Antona, Victor ; Nauwelaerts, Heidi ; Zubel, Angela ; Dummer, Reinhard. / Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. In: Oncotarget. 2019 ; Vol. 10, No. 19. pp. 1850-1859.
@article{d463ab50661f4c8489345b4deaa4f2c3,
title = "Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma",
abstract = "BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF V600 -mutant melanoma. We performed a nonrandomized, open-label phase II study, where 183 metastatic melanoma patients received binimetinib 45 mg / 60 mg twice-daily (BRAF arms), or binimetinib 45 mg twice-daily (NRAS arm). Biomarker analyses were prespecified as secondary and exploratory objectives. Here we report the extent of MAPK pathway inhibition by binimetinib, genetic pathway alterations of interest, and potential predictive markers for binimetinib efficacy. Twenty-five fresh pre- and post-dose tumor sample pairs were collected for biomarker analyses, which included assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor molecular status; and exploration of potential predictive biomarkers of efficacy of binimetinib. The postbaseline pERK and DUSP6 expression decreased across all arms; no association between reduced pERK or DUSP6 levels with clinical efficacy was observed. Genetic aberrations were similar to previously reported data on clinical melanoma samples. Genetic pathway alterations occurred predominantly within CDKN2A/B, PTEN, and TRRAP (BRAF-mutation) and CDKN2A/B, TP53, and NOTCH2 (NRAS-mutation). Several patients with BRAF mutations had amplification of genes on chromosome 7q; these patients tended to have shorter progression-free survival than other patients with BRAF-mutant melanoma. Further analysis of genetic alterations, including amplifications of growth factor genes, will determine utility as biomarkers for efficacy.",
keywords = "Binimetinib, Biomarker, MEK inhibitor, Melanoma, Phase II",
author = "{Van Herpen}, {Carla M.L.} and Agarwala, {Sanjiv S.} and Axel Hauschild and Carola Berking and {Thaddeus Beck}, J. and Dirk Schadendorf and Rob Jansen and Paola Queirolo and Ascierto, {Paolo A.} and Blank, {Christian U.} and Heinrich, {Michael C.} and Pal, {Rupam R.} and Adnan Derti and Victor Antona and Heidi Nauwelaerts and Angela Zubel and Reinhard Dummer",
year = "2019",
month = "3",
day = "1",
language = "English",
volume = "10",
pages = "1850--1859",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "19",

}

TY - JOUR

T1 - Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

AU - Van Herpen, Carla M.L.

AU - Agarwala, Sanjiv S.

AU - Hauschild, Axel

AU - Berking, Carola

AU - Thaddeus Beck, J.

AU - Schadendorf, Dirk

AU - Jansen, Rob

AU - Queirolo, Paola

AU - Ascierto, Paolo A.

AU - Blank, Christian U.

AU - Heinrich, Michael C.

AU - Pal, Rupam R.

AU - Derti, Adnan

AU - Antona, Victor

AU - Nauwelaerts, Heidi

AU - Zubel, Angela

AU - Dummer, Reinhard

PY - 2019/3/1

Y1 - 2019/3/1

N2 - BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF V600 -mutant melanoma. We performed a nonrandomized, open-label phase II study, where 183 metastatic melanoma patients received binimetinib 45 mg / 60 mg twice-daily (BRAF arms), or binimetinib 45 mg twice-daily (NRAS arm). Biomarker analyses were prespecified as secondary and exploratory objectives. Here we report the extent of MAPK pathway inhibition by binimetinib, genetic pathway alterations of interest, and potential predictive markers for binimetinib efficacy. Twenty-five fresh pre- and post-dose tumor sample pairs were collected for biomarker analyses, which included assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor molecular status; and exploration of potential predictive biomarkers of efficacy of binimetinib. The postbaseline pERK and DUSP6 expression decreased across all arms; no association between reduced pERK or DUSP6 levels with clinical efficacy was observed. Genetic aberrations were similar to previously reported data on clinical melanoma samples. Genetic pathway alterations occurred predominantly within CDKN2A/B, PTEN, and TRRAP (BRAF-mutation) and CDKN2A/B, TP53, and NOTCH2 (NRAS-mutation). Several patients with BRAF mutations had amplification of genes on chromosome 7q; these patients tended to have shorter progression-free survival than other patients with BRAF-mutant melanoma. Further analysis of genetic alterations, including amplifications of growth factor genes, will determine utility as biomarkers for efficacy.

AB - BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF V600 -mutant melanoma. We performed a nonrandomized, open-label phase II study, where 183 metastatic melanoma patients received binimetinib 45 mg / 60 mg twice-daily (BRAF arms), or binimetinib 45 mg twice-daily (NRAS arm). Biomarker analyses were prespecified as secondary and exploratory objectives. Here we report the extent of MAPK pathway inhibition by binimetinib, genetic pathway alterations of interest, and potential predictive markers for binimetinib efficacy. Twenty-five fresh pre- and post-dose tumor sample pairs were collected for biomarker analyses, which included assessment of binimetinib on MEK/MAPK signaling by pharmacodynamic analysis of pERK and DUSP6 expression in pre- vs post-dose tumor biopsies; identification of pERK and DUSP6 expression/efficacy correlations; assessment of baseline tumor molecular status; and exploration of potential predictive biomarkers of efficacy of binimetinib. The postbaseline pERK and DUSP6 expression decreased across all arms; no association between reduced pERK or DUSP6 levels with clinical efficacy was observed. Genetic aberrations were similar to previously reported data on clinical melanoma samples. Genetic pathway alterations occurred predominantly within CDKN2A/B, PTEN, and TRRAP (BRAF-mutation) and CDKN2A/B, TP53, and NOTCH2 (NRAS-mutation). Several patients with BRAF mutations had amplification of genes on chromosome 7q; these patients tended to have shorter progression-free survival than other patients with BRAF-mutant melanoma. Further analysis of genetic alterations, including amplifications of growth factor genes, will determine utility as biomarkers for efficacy.

KW - Binimetinib

KW - Biomarker

KW - MEK inhibitor

KW - Melanoma

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=85062760793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062760793&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85062760793

VL - 10

SP - 1850

EP - 1859

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -